The U.S. BPH surgical treatment market was valued at USD 714.48 million in 2024 and is projected to grow at a CAGR of 5.6% from 2025 to 2034. Segmentation by procedure type and care setting reveals nuanced dynamics in product differentiation, application‑specific growth, and value chain optimization. TURP remains the cornerstone procedure, but minimally invasive techniques like PUL, laser therapy, aquablation therapy, and water vapor thermal therapy (Rezum) are growing rapidly, driven by shorter hospital stays, perceived safety, and outpatient appeal.
In terms of procedure type, TURP continues to dominate due to its historical clinical credibility and relatively lower cost. However, PUL devices such as UroLift, laser techniques like HoLEP and GreenLight, and aquablation systems are gaining momentum through product differentiation and physician preference in ambulatory settings. Aquablation—developed by PROCEPT BioRobotics—uses autonomous robotics with real‑time imaging to reduce tissue trauma, illustrating a trend toward precision-based surgical innovation. Application‑specific growth is most notable in ambulatory surgery centers, where streamlined workflows and cost-effective reimbursement models incentivize less invasive options. Value chain optimization is evident in vertically integrated device portfolios, from consumables to clinical training support.
End-user segmentation shows hospitals continuing to manage inpatient and complex cases, but growth rates are highest in ASCs due to operational efficiencies and patient preference for outpatient procedures. Clinics and specialty urology centers also benefit from segment‑wise performance improvements as they adopt portable laser and vapor devices. Pricing differentiation is emerging through tiered bundles—some manufacturers offer device, consumable, and service contracts optimized for ASC efficiency, aligning with shifting provider economics.
Innovation is central to trends across all segments. Product differentiation is visible in laser systems that combine vaporization and enucleation, robotics like aquablation that increase procedural consistency, and steam-based Rezum therapy that enables local anesthesia delivery. Value chain optimization is reinforced by bundled service offerings and clinician education platforms supporting device adoption in clinic settings. Segment‑wise performance varies: TURP remains stable, laser and PUL segments grow double-digit in ASCs, and water vs. energy‑based therapies like Rezum gain traction for low-risk patients.
Competitive landscape (by share in procedural segments):
- Boston Scientific Corporation
- PROCEPT BioRobotics Corporation
- Medtronic
- Teleflex Incorporated
- Cook Medical
In conclusion, segmentation reveals varied growth patterns across the U.S. BPH surgical treatment market. Companies with differentiated products suited to ambulatory settings and cost‑effective application models will leverage value chain optimization for sustained competitive advantage. Investors should monitor segment‑wise performance and innovation pipelines, particularly where out‑of‑hospital delivery intersects with device evolution.
More Trending Latest Reports By Polaris Market Research:
Paper And Paperboard Packaging Market
Veterinary Endotracheal Tubes Market
English
Arabic
French
Spanish
Portuguese
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek